Stock Market Outlook: June Forecast

After one of the most iconic bull runs of the century, yesterday a rise in corona cases and a horrible outlook for the U.S. economy by the Federal Reserve ended it all with the biggest losses since March. The Golden Investor took his profits and sold all its assets including the majority of the miners portfolio. Nothing is safe as the second corona wave hits the United States. On the very short term The Golden Investor expects more losses.

Short Selling Possibilities For Bears

Lately it has been though for skeptical bears on the stock market. For now we look at some short-selling opportunities of stocks which won’t be able to keep up with the current rise of optimism with sufficient quarterly results.

The Indian Economy In Time Of Crisis: An Analysis

In this exclusive The Golden Investor article Charmi Shah provides us with an analytic overview of Indian financial policy during crises. In this article Charmi Shah tries to analyze how India recovered from the global financial crisis and the steps that are being taken by the government to overcome the pandemic.

#QE4EVER, The Broken Glass Fallacy Of Central Banks

The Golden Investor remains extremely skeptical on the current QE-measures by central banks. The dependency of quantitative easing of financial markets has come to a point where financial markets are more than ever disconnected from the real economy and are fully driven by financial stimulus of central banks.

Stock Buybacks: A Major Issue With Minor Attention

The last few years the amount of stock buybacks has increased significantly, last year the amount of stock buybacks exceeded to over one trillion dollars. Even as an investing journal, The Golden Investor is a great supporter of banning stock buybacks.

Stock Market Outlook: March Forecast

After big corona plays in March The Golden Investor continues to analyze the market and to stay ahead of other investors. After several stock markets saw their biggest losses in history even gold stocks tanked. In today’s monthly outlook we discuss the current catalysts and developments on stock markets.

Flow Traders (AEX:FLOW): Making Money On Volatility

Amid falling markets the Amsterdam-based Flow Traders soar. But as US-yields turn negative and commodities lose terrain it seems like all investing opportunities fade away. Insert Flow Traders (AEX:FLOW): This liquidity provider makes profit during mass swings on markets.

Lakeland Industries Inc. (LAKE): Safe-Haven Corona Virus Hedge

The Golden Investor continues to follow the outbreak of the novel corona virus thoroughly. Until recently the outbreak seemed centered in South-East Asia and the local spread was limited. Now it seems that the virus has found a way to nestle itself across the globe. Lakeland Industries (LAKE) is one of the biggest suppliers of protective gear in the United States and is making over-hours to catch up with global demand.

Stock Market Outlook: February Forecast

Amid dampening corona fears and Tesla’s blowup The Golden Investor will try to provide a accurate forecast for the month February. The Golden Investor discuss all main drivers which will determine investor’s portfolios this month. While investors hype over Tesla, The Golden Investor looks at more sustainable investing options for the long term.

NanoXplore (CVE:GRA): Graphene Manufacturer Scaling Up Production

NanoXplore (CVE:GRA) is a manufacturer and supplier of high-volume graphene powder for use in industrial markets as well as a producer of graphene-enhanced plastics and composite products. This year it is scaling up their production capacity of graphene from 25 tons/year to a stunning 4.000 tons/year. A potential bright and big future lies ahead for this company.

Cellnex Telecom (BME:CLNX): Endogenous Growth Faster Than 5G

The Golden Investor continues its tour around Europe. In Spain Cellnex Telecom is operating aggressively last few months. While Nokia (NYSE:NOK) and Ericsson (STO: ERIC) battle over the 5G roll-out, Cellnex Telecom (BME: CLNX) further strengthens their position as main infrastructure operator for wireless telecommunication in Europe.

Pharming Group NV (AEX:PHARM): Set For A Swelling Growth In 2020

Every now and then The Golden Investor covers interesting stocks overseas. Today we end up in The Netherlands where Pharming Group NV (AEX:PHARM) is heading to grow exponentially this year and the years beyond. Their main product being Ruconest, a treatment against angioedema-attacks in patients with hereditary angioedema.

“If The Entire System Collapses, The Gold Stock Provides A Collateral”

The PMI Manufacturing index contracted again in December, to 47.2 percent, a decrease of 0.9 percentage point from the November reading of 48.1 percent. The PMI manufacturing index contracted for the fifth straight month, at faster levels compared to November. This marks nine straight months of softening or contraction in manufacturing. Despite the Fed lowering interest rates three times last year, the future is looking less bright every month. With Trump and Iran not backing down, dark times seem to lie ahead. But not for gold.

bluebird bio (BLUE): Is This Bird Going To Fly?

Gene-therapy, it’s one of the most innovative and complex developments in the biotech-sector. This year bluebird bio (BLUE) will be one of the first companies to launch a commercial-stage gene therapy with their gene-therapy against beta-thalassemia called Zynteglo.

Lynas Corp Ltd (ASX:LYC): Rare-Earth Opportunity

As the only profitable rare-earth metal miner outside China, Lynas Corp Ltd (ASX:LYC) almost doubled in value when the trade war between the USA and China escalated. Investors speculated on potential restrictions on rare-earth metals. Reminding us of the situation in 2010 when China cut its export quotas significantly lower resulting in a rare-earth drought which led to Lynas Corp stock soaring to a five-fold of their 100-day moving average.

Beyond Meat (BYND): Beyond Its Value or Vegetarian Leader?

Ethan Brown’s enterprise enjoyed a big boost following its IPO, starting around $25, after the first day of trading shares soared to a stunning $65.75 end. The rally didn’t quit there, a high of $239.71 per stock was reached. But uncertain times ended that rally and since then the stock has lost a big part of its initial growth.

Clovis Oncology (CLVS): A Big Splash or A Burn of Cash?

Boosted by M&A hopes of investors on Wall-Street, Clovis Oncology (CLVS) skyrocketed in November. After the setback occurring after the bullish rally the stock gained momentum again when Jim Cramer said on CNBC’s show Mad Money that Clovis Oncology could be “a good spec”.

Subscribe To The Golden Investor

Get new content delivered directly to your inbox.